Health

Factbox-Vaccines delivered under COVAX sharing scheme for poorer countries

Published

3 years ago

February 26, 2022

The COVAX facility, backed by the World Health Organization (WHO) and the Global Alliance for Vaccines and Immunization (GAVI), has delivered 1.22 billion COVID-19 vaccine doses to 144 countries, GAVI data shows.

In December, COVAX set a target of achieving 70% COVID-19 immunization coverage by mid-2022.

The following tables list countries that have received vaccines under the scheme, sorted alphabetically:

AFRICA & MIDDLE EAST

COUNTRY LATEST DELIVERY DATE VACCINE TYPE POPULATION TOTAL

DELIVERY DELIVERED

Algeria 3.6 million December 24 J&J 44 million 6.0 million

Angola 801,000 December 25 Pfizer/BioNTech 33 million 14.8 million

Benin 336,000 November 4 J&J 12 million 1.1 million

Botswana 300,000 October 1 AstraZeneca/Oxford 2.5 million 560,460

Burkina Faso 504,000 December 22 J&J 21 million 1.1 million

Cameroon 336,000 November 5 J&J 27 million 1.0 million

Cape Verde 200,000 December 7 Pfizer/BioNTech 556,000 324,000

Central 168,300 November 19 J&J 4.8 million 806,700

African

Republic

Chad 117,000 October 5 Pfizer/BioNTech 16 million 217,620

Comoros 12,000 April 12 AstraZeneca/Oxford 870,000 12,000

Islands

Congo 168,000 November 15 J&J 5.5 million 470,400

Democratic 349,830 October 21 Pfizer/BioNTech 90 million 2.6 million

Republic of

Congo

Djibouti 151,200 July 17 J&J 988,000 175,200

Egypt 2.2 million February 20 Pfizer/BioNTech 102 million 29.0 million

Eswatini 100,620 October 6 Pfizer/BioNTech 1.1 million 429,420

Ethiopia 13.1 February 2 J&J 115 million 27.5 million

million

Gabon 101,790 November 1 Pfizer/BioNTech 2.2 million 370,410

Gambia 38,400 August 22 AstraZeneca/Oxford 2.4 million 376,800

Ghana 1.7 million December 24 Pfizer/BioNTech 31 million 16.3 million

Guinea 168,000 November 14 J&J 13 million 1.7 million

Guinea-Bissau 28,800 August 18 AstraZeneca/Oxford 2.0 million 360,000

Iran 700,000 January 14 AstraZeneca/Oxford 84 million 5.7 million

Iraq 500,000 August 14 Pfizer/BioNTech 40 million 836,000

Ivory Coast 816,660 January 3 Pfizer/BioNTech 26 million 8.6 million

Jordan 146,400 June 3 AstraZeneca/Oxford 10 million 436,800

Kenya 500,000 January 29 Pfizer/BioNTech 54 million 16.7 million

Lebanon 613,340 December 22 N/A 6.8 million 982,940

Lesotho 169,070 November 19 J&J 2.1 million 644,090

Liberia 168,000 November 27 J&J 5.1 million 830,400

Libya 1.2 million December 20 Pfizer/BioNTech 6.9 million 1.9 million

Madagascar 240,000 February 17 J&J 28 million 1.9 million

Malawi 360,000 October 23 AstraZeneca/Oxford 19 million 1.8 million

Mali 50,400 January 7 AstraZeneca/Oxford 20 million 1.7 million

Mauritania 201,600 February 7 AstraZeneca/Oxford 4.6 million 2.2 million

Mauritius 203,580 January 12 Pfizer/BioNTech 1.3 million 387,270

Morocco 1.5 million January 29 Pfizer/BioNTech 37 million 2.7 million

Mozambique 1.2 million February 11 AstraZeneca/Oxford 31 million 8.4 million

Namibia 168,000 February 18 J&J 2.5 million 492,800

Niger 398,000 February 4 Pfizer/BioNTech 24 million 1.6 million

Nigeria 2.0 million February 7 J&J 206 million 17.2 million

Palestinian 203,580 January 31 Pfizer/BioNTech 4.7 million 1.3 million

Territories

Rwanda 1.1 million January 15 N/A 13 million 3.9 million

Sao Tome and 24,000 March 3 AstraZeneca/Oxford 219,000 24,000

Principe

Senegal 302,400 February 10 J&J 17 million 3.2 million

Seychelles 39,780 December 17 Pfizer/BioNTech 98,460 74,880

Sierra Leone 168,000 November 23 J&J 8.0 million 785,310

Somalia 336,500 November 7 J&J 16 million 1.2 million

South Africa 5.6 million July 31 Pfizer/BioNTech 59 million 5.6 million

South Sudan 336,000 December 21 J&J 11 million 908,450

Sudan 604,800 February 16 J&J 44 million 3.9 million

Syria 4.0 million January 26 J&J 17 million 5.7 million

Tanzania 1.6 million January 19 Pfizer/BioNTech 60 million 4.7 million

Togo 633,600 November 25 J&J 8.3 million 3.0 million

Tunisia 310,050 January 28 Pfizer/BioNTech 12 million 4.4 million

Uganda 433,300 February 16 Moderna 46 million 11.7 million

Yemen 100,800 February 24 AstraZeneca/Oxford 30 million 2.2 million

Zambia 907,200 January 28 N/A 18 million 4.0 million

Zimbabwe 2.6 million January 19 N/A 15 million 3.5 million

EUROPE

COUNTRY LATEST DELIVERY VACCINE TYPE POPULATION TOTAL

DELIVERY DATE DELIVERED

Albania 40,800 June 2 AstraZeneca/Oxford 2.8 million 120,000

Armenia 187,200 September 5 AstraZeneca/Oxford 3.0 million 261,200

Azerbaijan 84,000 April 4 AstraZeneca/Oxford 10 million 84,000

Bosnia 32,760 May 10 Pfizer/BioNTech 3.3 million 82,560

Georgia 43,200 March 13 AstraZeneca/Oxford 3.7 million 43,200

Kosovo 515,970 February 10 Pfizer/BioNTech 1.8 million 1.2 million

Moldova 100,620 January 27 Pfizer/BioNTech 2.6 million 744,620

Montenegro 24,000 March 28 AstraZeneca/Oxford 622,000 24,000

North 250,380 February 7 Pfizer/BioNTech 2.1 million 312,780

Macedonia

Serbia 115,200 August 25 AstraZeneca/Oxford 6.9 million 292,800

Ukraine 1.0 million January 19 Pfizer/BioNTech 44 million 8.8 million

ASIA & PACIFIC

COUNTRY LATEST DELIVERY DELIVERY VACCINE TYPE POPULATION TOTAL

DATE DELIVERED

Afghanistan 2.0 million February 2 J&J 39 million 9.0 million

Bangladesh 342,400 February 2 Pfizer/BioNTech 165 million 34.8 million

Brunei 24,000 April 2 AstraZeneca/Oxford 437,000 24,000

Cambodia 300,000 December 19 AstraZeneca/Oxford 17 million 2.9 million

East Timor 100,620 February 12 Pfizer/BioNTech 1.3 million 494,040

Fiji 50,400 November 18 Moderna 896,000 302,480

Indonesia 2.6 million January 28 AstraZeneca/Oxford 274 million 48.8 million

Kiribati 56,000 August 21 AstraZeneca/Oxford 119,000 104,000

Kyrgyzstan 149,760 February 1 Pfizer/BioNTech 6.6 million 800,300

Laos 1.7 million January 26 Pfizer/BioNTech 7.3 million 7.6 million

Malaysia 559,200 September AstraZeneca/Oxford 32 million 1.4 million

Maldives 210,600 January 28 Pfizer/BioNTech 541,000 664,540

Mongolia 899,730 October 6 Pfizer/BioNTech 3.3 million 1.3 million

Nauru 7,200 April 2 AstraZeneca/Oxford 10,830 7,200

Nepal 800,000 February 7 AstraZeneca/Oxford 29 million 14.2 million

Pakistan 1.5 million December 28 Moderna 221 million 39.1 million

Papua New 302,400 August 6 J&J 8.9 million 580,400

Guinea

Philippines 3.4 million February 15 Pfizer/BioNTech 110 million 51.8 million

Samoa 112,000 August 23 AstraZeneca/Oxford 198,410 136,000

Solomon 100,620 November 16 Pfizer/BioNTech 687,000 209,420

Islands

Sri Lanka 820,000 December 20 Pfizer/BioNTech 22 million 5.0 million

Tajikistan 501,200 February 21 AstraZeneca/Oxford 9.5 million 5.4 million

Tonga 7,000 February 15 N/A 106,000 67,800

Tuvalu 4,800 April 8 AstraZeneca/Oxford 11,800 4,800

Uzbekistan 2.8 million February 17 Moderna 34 million 12.7 million

Vanuatu 24,000 May 19 AstraZeneca/Oxford 307,000 24,000

Vietnam 6.3 million January 25 Pfizer/BioNTech 97 million 38.7 million

AMERICAS

COUNTRY LATEST DELIVERY VACCINE TYPE POPULATION TOTAL

DELIVERY DATE DELIVERED

Antigua and 19,200 November 22 N/A 98,000 60,000

Barbuda

Argentina 960,400 October 12 AstraZeneca/Oxford 45 million 3.9 million

Bahamas 57,330 October 18 Pfizer/BioNTech 393,000 124,530

Barbados 14,040 December 16 Pfizer/BioNTech 287,000 114,840

Belize 58,500 October 26 Pfizer/BioNTech 398,000 159,300

Bermuda 9,600 April 6 AstraZeneca/Oxford 64,000 9,600

Bolivia 1.3 million February 16 Pfizer/BioNTech 12 million 8.0 million

Brazil 2.0 million September 20 Sinovac 213 million 11.9 million

Chile 331,000 May 20 AstraZeneca/Oxford 19 million 489,400

Colombia 5.5 million January 3 Pfizer/BioNTech 51 million 16.5 million

Costa Rica 1.0 million February 11 Pfizer/BioNTech 5.1 million 1.4 million

Dominica 30,240 February 4 Moderna 72,000 133,920

Dominican 184,800 August 27 AstraZeneca/Oxford 11 million 463,200

Republic

Ecuador 1.5 million February 15 Pfizer/BioNTech 18 million 3.8 million

El Salvador 188,370 August 27 Pfizer/BioNTech 6.5 million 3.6 million

Grenada 69,030 December 16 Pfizer/BioNTech 113,000 114,630

Guatemala 680,940 January 27 Pfizer/BioNTech 17 million 5.0 million

Guyana 28,800 January 14 J&J 787,000 291,540

Haiti 151,200 February 14 Moderna 11 million 1.1 million

Honduras 250,040 October 28 Moderna 9.9 million 4.8 million

Jamaica 100,000 February 21 AstraZeneca/Oxford 3.0 million 1.7 million

Mexico 2.2 million May 27 AstraZeneca/Oxford 129 million 3.3 million

Nicaragua 993,600 January 24 J&J 6.6 million 4.7 million

Panama 74,400 September 15 AstraZeneca/Oxford 4.3 million 148,800

Paraguay 466,830 January 24 Pfizer/BioNTech 7.1 million 1.7 million

Peru 1.2 million November 10 Sinopharm 33 million 3.6 million

Saint Kitts and 21,600 April 7 AstraZeneca/Oxford 53,000 21,600

Nevis

Saint Lucia 7,200 December 28 J&J 184,000 197,430

Saint Vincent 70,200 December 14 Pfizer/BioNTech 111,000 115,800

and the

Grenadines

Suriname 64,800 December 14 AstraZeneca/Oxford 587,000 144,000

Trinidad and 84,000 November 27 Sinopharm 1.4 million 185,200

Tobago

Uruguay 50,400 September 1 AstraZeneca/Oxford 3.5 million 148,800

Venezuela 3.1 million January 17 Sinopharm 28 million 12.1 million

Sources: WHO, UNICEF, GAVI, releases from local authorities

(Compiled by Marta Frackowiak, Antonis Pothitos, Boleslaw Lasocki, Antonis Triantafyllou, Aleksandra Jasiurska and Elizaveta Gladun; Edited by David Evans and Bernadette Baum)

Health

How many Nova Scotians are on the doctor wait-list? Number hit 160,000 in June

Published

17 hours ago

September 11, 2024

Anne Joseph

HALIFAX – The Nova Scotia government says it could be months before it reveals how many people are on the wait-list for a family doctor.

The head of the province’s health authority told reporters Wednesday that the government won’t release updated data until the 160,000 people who were on the wait-list in June are contacted to verify whether they still need primary care.

Karen Oldfield said Nova Scotia Health is working on validating the primary care wait-list data before posting new numbers, and that work may take a matter of months. The most recent public wait-list figures are from June 1, when 160,234 people, or about 16 per cent of the population, were on it.

“It’s going to take time to make 160,000 calls,” Oldfield said. “We are not talking weeks, we are talking months.”

The interim CEO and president of Nova Scotia Health said people on the list are being asked where they live, whether they still need a family doctor, and to give an update on their health.

A spokesperson with the province’s Health Department says the government and its health authority are “working hard” to turn the wait-list registry into a useful tool, adding that the data will be shared once it is validated.

Nova Scotia’s NDP are calling on Premier Tim Houston to immediately release statistics on how many people are looking for a family doctor. On Tuesday, the NDP introduced a bill that would require the health minister to make the number public every month.

“It is unacceptable for the list to be more than three months out of date,” NDP Leader Claudia Chender said Tuesday.

Chender said releasing this data regularly is vital so Nova Scotians can track the government’s progress on its main 2021 campaign promise: fixing health care.

The number of people in need of a family doctor has more than doubled between the 2021 summer election campaign and June 2024. Since September 2021 about 300 doctors have been added to the provincial health system, the Health Department said.

“We’ll know if Tim Houston is keeping his 2021 election promise to fix health care when Nova Scotians are attached to primary care,” Chender said.

This report by The Canadian Press was first published Sept. 11, 2024.

Source link

Health

Newfoundland and Labrador monitoring rise in whooping cough cases: medical officer

Published

2 days ago

September 10, 2024

Anne Joseph

ST. JOHN’S, N.L. – Newfoundland and Labrador‘s chief medical officer is monitoring the rise of whooping cough infections across the province as cases of the highly contagious disease continue to grow across Canada.

Dr. Janice Fitzgerald says that so far this year, the province has recorded 230 confirmed cases of the vaccine-preventable respiratory tract infection, also known as pertussis.

Late last month, Quebec reported more than 11,000 cases during the same time period, while Ontario counted 470 cases, well above the five-year average of 98. In Quebec, the majority of patients are between the ages of 10 and 14.

Meanwhile, New Brunswick has declared a whooping cough outbreak across the province. A total of 141 cases were reported by last month, exceeding the five-year average of 34.

The disease can lead to severe complications among vulnerable populations including infants, who are at the highest risk of suffering from complications like pneumonia and seizures. Symptoms may start with a runny nose, mild fever and cough, then progress to severe coughing accompanied by a distinctive “whooping” sound during inhalation.

“The public, especially pregnant people and those in close contact with infants, are encouraged to be aware of symptoms related to pertussis and to ensure vaccinations are up to date,” Newfoundland and Labrador’s Health Department said in a statement.

Whooping cough can be treated with antibiotics, but vaccination is the most effective way to control the spread of the disease. As a result, the province has expanded immunization efforts this school year. While booster doses are already offered in Grade 9, the vaccine is now being offered to Grade 8 students as well.

Public health officials say whooping cough is a cyclical disease that increases every two to five or six years.

Meanwhile, New Brunswick’s acting chief medical officer of health expects the current case count to get worse before tapering off.

A rise in whooping cough cases has also been reported in the United States and elsewhere. The Pan American Health Organization issued an alert in July encouraging countries to ramp up their surveillance and vaccination coverage.

This report by The Canadian Press was first published Sept. 10, 2024.

Source link

Health

Bizarre Sunlight Loophole Melts Belly Fat Fast!

Published

2 days ago

September 10, 2024

Sven Eggers

Product Name: Bizarre Sunlight Loophole Melts Belly Fat Fast!

Click here to get Bizarre Sunlight Loophole Melts Belly Fat Fast! at discounted price while it’s still available…

All orders are protected by SSL encryption – the highest industry standard for online security from trusted vendors.

Bizarre Sunlight Loophole Melts Belly Fat Fast! is backed with a 60 Day No Questions Asked Money Back Guarantee. If within the first 60 days of receipt you are not satisfied with Wake Up Lean™, you can request a refund by sending an email to the address given inside the product and we will immediately refund your entire purchase price, with no questions asked.